GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

PF-07081532

Company
Pfizer
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT04148209

    Study of Single Ascending Doses of PF-07081532 in Healthy Adult Participants

    Not yet reported Pfizer 22 participants Est. completion 2020-03-17 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT04305587

    Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

    Not yet reported Pfizer 66 participants Est. completion 2021-07-14 2 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT05158244

    Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

    Not yet reported Pfizer 34 participants Est. completion 2022-06-15 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT05478603

    A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction

    Not yet reported Pfizer 24 participants Est. completion 2023-04-05 2 sites Stand-alone
    Other conditions: Hepatic Impairment, Healthy Volunteers
    View official trial listing →
  • Terminated NCT NCT05510245

    A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction

    Not yet reported Pfizer 18 participants Est. completion 2023-07-20 2 sites Stand-alone
    Type 2 diabetes Other conditions: Renal Impairment
    View official trial listing →
  • Terminated NCT NCT05579977

    Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity

    Not yet reported Pfizer 902 participants Est. completion 2023-09-22 90 sites Stand-alone
    Other conditions: Diabetes Mellitus, Obesity
    View official trial listing →
  • Completed NCT NCT05652647

    A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men

    Not yet reported Pfizer 6 participants Est. completion 2023-03-15 1 site Stand-alone
    Other conditions: Healthy Participants
    View official trial listing →
  • Terminated NCT NCT05671653

    A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range

    Not yet reported Pfizer 32 participants Est. completion 2023-11-03 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT05677867

    A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

    Not yet reported Pfizer 20 participants Est. completion 2023-03-14 1 site Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Completed NCT NCT05745701

    A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults

    Not yet reported Pfizer 16 participants Est. completion 2023-05-29 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Terminated NCT NCT05788328

    A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants

    Not yet reported Pfizer 16 participants Est. completion 2023-09-11 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.